Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cymabay Therapeutics 7601 DUMBARTON CIRCLE FREMONT CA 94555 USA

www.cymabay.com P: 510-293-8800 F: 510-293-9090

Description:

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.

Key Statistics

Overview:

Market Capitalization, $K 3,726,235
Enterprise Value, $K 3,519,695
Shares Outstanding, K 114,724
Annual Sales, $ 31,070 K
Annual Net Income, $ -105,370 K
Last Quarter Sales, $ 60 K
Last Quarter Net Income, $ -41,900 K
EBIT, $ -101,690 K
EBITDA, $ -108,870 K
60-Month Beta 0.32
% of Insider Shareholders 7.00%
% of Institutional Shareholders 95.03%
Float, K 106,693
% Float 93.00%
Short Volume Ratio 0.31

Growth:

1-Year Return 262.50%
3-Year Return 623.39%
5-Year Return 144.58%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 21.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.35 on 02/28/24
Next Earnings Date 03/21/24
Earnings Per Share ttm -0.97
EPS Growth vs. Prev Qtr -9.38%
EPS Growth vs. Prev Year -16.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CBAY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -50.72%
Return-on-Assets % -31.04%
Profit Margin % -339.14%
Debt/Equity 0.00
Price/Sales 119.88
Price/Cash Flow N/A
Price/Book 12.60
Book Value/Share 2.58
Interest Coverage -4.56
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar